Mochida-discovered drug launches and reshapes Mochida stock's pipeline story

Published on 10/13/2026 at 00:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MTA-304 was linked to Mochida on October 9, 2026, for Phase II in 2027. Mochida stock posted JPY 31.72 billion revenue in its latest quarter.

Key points in brief

Mochida-discovered MTA-304 entered Mentara Therapeutics' Parkinson's disease program on October 9, 2026.
The compound is planned for a Phase II trial in 2027 after three Phase I studies involving 86 participants.
Mochida reported JPY 31.72 billion in latest-quarter revenue and JPY 3.18 billion in net income.
The next earnings report is scheduled for October 30, 2026, according to TradingView.

Mochida, JP3922800002, Illustration mit AI erstellt.

Mochida Pharmaceutical (ISIN JP3922800002) gained a new development angle on October 9, 2026, when Mentara Therapeutics launched with MTA-304, a PDE10A inhibitor originally discovered by Mochida. AllSci reported that Mentara plans to begin a Phase II trial for levodopa-induced dyskinesia in 2027.

Three milestones shape the pipeline

On June 24, 2026, Mochida's fiscal-year filing showed revenue of JPY 116.95 billion and net income of JPY 7.90 billion for the fiscal year ended March 31, 2026, according to Yuhodb.

On August 3, 2026, Mochida's latest quarterly release recorded JPY 31.72 billion in revenue, JPY 3.18 billion in net income and JPY 89.80 in earnings per share, according to Investing.com. Revenue rose from JPY 29.46 billion in the preceding quarter, while net income increased from JPY 1.56 billion.

What does the pipeline link add?

The MTA-304 connection gives Mochida a research-origin story beyond its reported earnings. AllSci said three Phase I studies involved 86 participants and described a favorable safety and tolerability profile, while the planned Phase II trial targets a complication of long-term Parkinson's disease treatment.

The financial terms of the Mentara transaction were not disclosed by AllSci, so the immediate relevance is scientific rather than a quantified licensing contribution. For investors, the key measurable contrast is between Mochida's JPY 31.72 billion latest-quarter revenue and its JPY 3.18 billion net income, which implies a 10.02 percent net margin for that period.

October 30 is the next date

TradingView lists October 30, 2026, as Mochida's next earnings date. That report will provide the next direct test of whether the latest quarterly revenue and profit trend is continuing.

Mochida remains a Tokyo pharmaceutical stock

Mochida's market capitalization was JPY 108.7 billion as of October 9, 2026, while its Tokyo-listed shares stood within a 52-week range of JPY 2,929.00 to JPY 3,965.00. The company develops, manufactures and sells prescription pharmaceuticals, and its shares trade on the Tokyo Stock Exchange Prime Market.

The further course of trading is shown by the continuously updated real-time quote of Mochida stock.